M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Epinephrine for cardiac arrest: Better survival, more brain damage
PARAMEDIC2 clears uncertainties in treating out-of-hospital cardiac arrest.
News
NAFLD less common, more severe in black children
ORLANDO – Overall prevalence in obese kids: 42%
News
Stress balls, hand-holding no help during dermatology procedures
Standard measures may be enough to relieve patient anxiety.
News
Intranasal naloxone promising for type 1 hypoglycemia
ORLANDO – This development could help prevent autonomic failure in T1DM patients.
News
USPSTF: Insufficient evidence for ABI screening in asymptomatic adults
Evidence is lacking even in high-risk patients.
News
USPSTF: Nontraditional CVD risk factors not ready for prime time
Utility unproven, but experts make a case for one particular measure.
News
Uric acid tied to pediatric diabetic kidney disease
ORLANDO – A new indication for allopurinol?
News
Adalimumab strikes out for aortic inflammation in psoriasis
ORLANDO – Ustekinumab shows promise, but “we are still not certain.”
Video
Diabetes patients pushed into high-deductible plans
ORLANDO – The proportion of diabetes patients enrolled in high-deductible health plans jumped from 10% in 2005 to...
Video
Switch back to human insulin a viable money saver
ORLANDO – Hypoglycemia admissions were flat while HbA1c rose slightly.
News
Patients going without as insulin prices skyrocket
ORLANDO – A quarter of diabetes patients use less insuling than prescribed because of cost, and have poorer glycemic control
News
JAK inhibitor therapy promising for refractory dermatomyositis
ORLANDO – A pilot study of tofacitinib for refractory dermatomyositis in adults is underway.
News
Midlife retinopathy predicts ischemic stroke
LOS ANGELES – No tie to hemorrhagic strokes observed in review of more than 10,000 patients followed for nearly 20 years.
News
Magnetic LES augmentation for Barrett’s regression debated
A better solution?